Increasing Incidence Of Infectious Diseases Fueling The Growth Of The Market Due To Rising Travel And Pathogen Spread Is Supporting Development Across The Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market
The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Increase In Market Value Is Predicted For The Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market During The 2026–2030 Period?
The next-generation sequencing (ngs)-based molecular diagnostics market has demonstrated substantial growth in recent years. This market is anticipated to expand from $2.26 billion in 2025 to $2.43 billion in 2026, at a compound annual growth rate (CAGR) of 7.6%. Historically, this growth can be attributed to several factors including increased genetic disorder testing, the development of high-throughput sequencing, growing awareness of molecular diagnostics, its adoption in clinical labs, and technological improvements in sequencing reagents.
The next-generation sequencing (ngs)-based molecular diagnostics market size is anticipated to experience robust growth in the upcoming years. This market is set to expand to $3.23 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.3%. The expansion within this forecast period can be attributed to the incorporation of AI and machine learning in diagnostic processes, the broadening of cloud-based genomic platforms, the development of compact and point-of-care sequencing instruments, the rising adoption of personalized medicine applications, and collaborations between diagnostics and biotechnology firms. Significant trends for the forecast period include AI-assisted molecular diagnostics, cloud genomic analysis platforms, portable sequencing devices, the integration of bioinformatics pipelines, and rapid disease marker detection.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28281&type=smp
Which Growth Drivers Are Expected To Support The Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market Forward?
The escalating occurrence of infectious diseases is anticipated to fuel the expansion of the next-generation sequencing (NGS)-based molecular diagnostics market. Infectious diseases are conditions caused by microorganisms such as bacteria, viruses, fungi, or parasites that invade the body, multiply, and disrupt normal bodily functions. The prevalence of these diseases is rising as increased travel and migration accelerate the spread of pathogens across regions and borders. Next-generation sequencing (NGS)-based molecular diagnostics aids in the detection of infectious diseases by offering comprehensive and precise analysis of pathogens. It shortens diagnostic time through the simultaneous identification of multiple microorganisms, thereby enhancing treatment accuracy and patient care. For instance, in February 2024, the UK Health Security Agency, a UK-based government agency, stated that tuberculosis cases in England reached 4,850 in 2023, representing a 10.7% rise from 4,380 cases in 2022. Consequently, the increasing incidence of infectious diseases is propelling the growth of the next-generation sequencing (NGS)-based molecular diagnostics market.
How Is Segment Classification Applied In The Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market?
The next-generation sequencing (ngs)-based molecular diagnostics market covered in this report is segmented –
1) By Type: Instruments, Reagents And Consumables, Software And Services, Panels And Assays, Sample Preparation Kits
2) By Application: Microbiology, Infectious Diseases, Oncology, Genetic Tests, Other Applications
3) By End User: Research Centers And Academics, Hospitals And Clinical Laboratories, Other End Users
Subsegments:
1) By Instruments: Benchtop Sequencers, High-Throughput Sequencers, Portable Or Handheld Sequencers, Clinical Or Diagnostic Sequencers, Automated Library Preparation Systems, Data Analysis And Bioinformatics Hardware
2) By Reagents And Consumables: Sequencing Reagents And Kits, Library Preparation Reagents, Target Enrichment Reagents, Amplification Reagents, Sequencing Flow Cells And Chips, Deoxyribonucleic Acid (DNA) Or Ribonucleic Acid (RNA) Extraction Reagents, Quality Control Reagents
3) By Software And Services: Data Analysis Software, Bioinformatics Pipelines, Cloud-Based Genomic Platforms, Clinical Interpretation Tools, Data Storage And Management Services, Custom Bioinformatics Services, Genomic Database Services
4) By Panels And Assays: Oncology Panels, Infectious Disease Panels, Carrier Screening Panels, Reproductive Health Panels, Rare Disease Or Genetic Disorder Panels, Pharmacogenomics Panels, Whole-Exome Or Whole-Genome Assays
5) By Sample Preparation Kits: Deoxyribonucleic Acid (DNA) Extraction Kits, Ribonucleic Acid (RNA) Extraction Kits, Library Preparation Kits, Target Enrichment Kits, Amplification And Cleanup Kits, Single-Cell Preparation Kits, Low-Input Or Degraded Sample Kits
What Trends Are Driving Changes In The Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market?
Major companies within the next-generation sequencing (NGS)-based molecular diagnostics market are concentrating on developing advanced NGS-based panels to enhance the accuracy, accessibility, and efficiency of genetic testing. NGS panels are specific sets of genes or genomic regions analyzed simultaneously using NGS technology to detect clinically relevant mutations, leading to faster and more precise molecular diagnostics. For instance, in April 2024, Pillar Biosciences, a US-based diagnostics company, received FDA approval for its oncoReveal CDx pan-cancer solid tumor IVD kit, which analyzes 22 clinically relevant genes in a single multiplex reaction. Designed for use with Illumina’s MiSeq Dx system, this panel supports a sample-to-report time of approximately 48 hours and can process up to 46 clinical samples per run. The OncoReveal CDx includes companion diagnostic claims for KRAS (for EGFR-targeted therapy in colorectal cancer) and EGFR (TKI therapy in non–small-cell lung cancer), enabling more comprehensive and efficient detection of actionable genomic alterations to improve clinical decision-making.
Which Organizations Are Involved In The Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market?
Major companies operating in the next-generation sequencing (ngs)-based molecular diagnostics market are Thermo Fisher Scientific, Siemens Healthineers AG, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., Qiagen N.V., Amoy Diagnostics Co. Ltd., Tempus Labs Inc., Myriad Genetics Inc., Epigenomics AG, Precision for Medicine Inc., Invitae Corporation, NeoGenomics Laboratories Inc., Guardant Health Inc., Caris Life Sciences Inc., Foundation Medicine Inc., Oxford Nanopore Technologies Ltd., Freenome Inc., Burning Rock Biotech, Element Biosciences Inc., Asuragen Inc., Bionano Genomics Inc., Genomic Health Inc., TATAA Biocenter AB
Access The Complete Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market Report:
Which Regional Market Leads The Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market?
North America was the largest region in the next-generation sequencing (NGS)-based molecular diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation sequencing (ngs)-based molecular diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access a Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market Report for Deeper Competitive Insights
Browse Through More Reports Similar to the Global Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market 2026, By The Business Research Company
Ngs Based Rna Sequencing Market Report 2026
https://www.thebusinessresearchcompany.com/report/ngs-based-rna-sequencing-global-market-report
Next Generation Sequencing Market 2026
https://www.thebusinessresearchcompany.com/report/next-generation-sequencing-market
Point Of Care Molecular Diagnostics Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
